74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Qiagen NV
Open
SectorHealthcare
40.21 1.44
Overview
Share price change
24h
Min
39.77
Max
41.36
Income | -9.7M 88M |
|---|---|
Sales | 19M 521M |
P/E Sector Avg | 105.658 63.778 |
EPS | 0.61 |
Dividend yield | 2.94 |
Profit margin | 16.946 |
Employees | 5,700 |
EBITDA | 12M 190M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +22.86% upside |
Dividend yield Sector Avg | 2.94% 2.39% |
|---|---|
Next Earnings | 28 Apr 2025 |
Market Cap | 8.7B |
|---|---|
Previous open | 38.77 |
Previous close | 40.21 |
News Sentiment
By Acuity
26%
74%
73 / 386 Healthcare
Qiagen NV Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Qiagen NV Forecast
Price Target
By TipRanks
22.86% upside
12 Months Forecast
Average 48.53 USD 22.86%
High 55 USD
Low 42 USD
Based on 12 Wall Street analysts offering 12 month price targets forQiagen NV - Dist in the last 3 months.
Sentiment
By Acuity
73 / 386 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Qiagen NV
Qiagen N.V. offers sample to insight solutions that transform biological materials into molecular insights. The company provides sample technology consumables, such as nucleic stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID and forensics assay consumables, such as STR assays for human ID, and assays for food contamination; PCR instruments include digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It also offers predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a collaboration with the U.S. FBI; and with Bio-Manguinhos/Fiocruz to detect malaria and dengue. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
